Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) were down 0.7% during mid-day trading on Friday after Barclays lowered their price target on the stock from $1,025.00 to $975.00. Barclays ...

Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...

Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio ...

Nearly one-third of those patients were paying $35 or far more per month in 2019, according to the latest available data from ...

The global injection pen market is expanding at a fast rate with the growing prevalence of chronic diseases, and increasing demand for convenient self-administration options. This trend is a move ...

GHP Investment Advisors Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.1% during the third ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, ...